Amgen Halts Phase 2 HZN-1116 Trial in Sjögren’s: What Investors Should Know

Amgen Inc (AMGN) announced an update on their ongoing clinical study.

Amgen Inc. (AMGN) has halted a mid-stage study titled “A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome.” The goal was to test if HZN-1116 could safely ease symptoms of this chronic autoimmune condition, a niche area with limited treatment options.

The main treatment tested was HZN-1116, also known as VIB1116 or AMG 329, given as an under-the-skin injection. The drug was compared with a matching placebo to see whether different dose levels could provide meaningful symptom relief while keeping side effects in check.

The trial used a randomized design, meaning participants were assigned by chance to HZN-1116 or placebo. It was double-blind with a parallel setup, so neither patients nor study staff knew who got which treatment, and the core aim was to evaluate treatment benefit rather than prevention or diagnosis.

The study was first submitted on 16 February 2024, marking its formal start in the regulatory system. The latest update was filed on 6 May 2026, when the overall status was changed to “terminated,” signaling that the study was stopped early and will not reach the originally planned completion.

This termination is a modest negative for Amgen’s pipeline narrative, especially in immunology, and may temper some long-term growth expectations around HZN-1116. For investors, it underscores development risk in autoimmune diseases and may slightly benefit peers with late-stage Sjögren’s programs, though the direct earnings impact for AMGN appears limited at this stage.

The study has been terminated and the record remains updated, with further details available on the ClinicalTrials portal.

To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.